The CHA2DS2-VASc score and in-hospital mortality in patients with COVID-19: A multicenter retrospective cohort study [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2020; 48(7): 656-663 | DOI: 10.5543/tkda.2020.03488

The CHA2DS2-VASc score and in-hospital mortality in patients with COVID-19: A multicenter retrospective cohort study

Alaa Quisi1, Gökhan Alıcı2, Hazar Harbalıoğlu3, Ömer Genç4, Fahri Er4, Samir Allahverdiyev5, Abdullah Yıldırım6, Ibrahim Halil Kurt6
1Department of Cardiology, Medline Hospital Adana, Adana, Turkey
2Department of Cardiology, Okmeydanı Training and Research Hospital, İstanbul, Turkey
3Department of Cardiology, Düzce Atatürk State Hospital, Düzce, Turkey
4Department of Cardiology, Ağrı State Hospital, Ağrı, Turkey
5Department of Cardiology, İstanbul Aydın University VM Medical Park Florya Hospital, İstanbul, Turkey
6Department of Cardiology, Adana City Training and Research Hospital, Adana, Turkey


OBJECTIVE
Coronavirus disease 2019 (COVID-19) is an infectious disease that was first reported in December 2019 in Wuhan, China, and has since spread rapidly around the world, resulting in the ongoing COVID-19 pandemic. The CHA2DS2-VASc score is a well‐validated risk stratification tool for predicting stroke in atrial fibrillation (AFib), as well as morbidity and mortality in several entities. The aim of this study was to evaluate the relationship between the CHA2DS2-VASc score and in-hospital mortality in patients with COVID-19, regardless of AFib.

METHODS
This multicenter, retrospective study included a total of 349 patients with COVID-19 who were hospitalized between March 15 and April 15, 2020. The CHA2DS2-VASc score of each patient was calculated. Mortality outcomes were followed up until April 25, 2020.

RESULTS
The CHA2DS2-VASc score was significantly higher in non-survivor COVID-19 patients than in survivor COVID-19 patients (p<0.001). Forward stepwise logistic regression analysis demonstrated that a CHA2DS2-VASc score of ≥3 (odds ratio [OR]: 12.613, 95% confidence interval [CI]: 3.092–51.451; p<0.001), and the leukocyte count (OR: 1.327, 95% CI: 1.145-1.538; p<0.001), C-reactive protein level (OR: 1.010, 95% CI: 1.002–1.018; p=0.012), and ferritin level (OR: 1.005, 95% CI: 1.003–1.007; p<0.001) on admission were independent predictors of in-hospital mortality of COVID-19 patients.

CONCLUSION
The CHA2DS2-VASc score predicted in-hospital mortality in patients with COVID-19, regardless of AFib.

Keywords: CHA2DS2-VASc, COVID-19; mortality.

How to cite this article
Alaa Quisi, Gökhan Alıcı, Hazar Harbalıoğlu, Ömer Genç, Fahri Er, Samir Allahverdiyev, Abdullah Yıldırım, Ibrahim Halil Kurt. The CHA2DS2-VASc score and in-hospital mortality in patients with COVID-19: A multicenter retrospective cohort study. Turk Kardiyol Dern Ars. 2020; 48(7): 656-663

Corresponding Author: Alaa Quisi, Türkiye
© Copyright 2020 Archives of the Turkish Society of Cardiology
LookUs & Online Makale